Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;104(Pt A):106856.
doi: 10.1016/j.yebeh.2019.106856. Epub 2020 Jan 15.

Quality of life and its association with comorbidities and adverse events from antiepileptic medications: Online survey of patients with epilepsy in Australia

Jeremy M Welton  1 , Christine Walker  2 , Kate Riney  3 , Alvin Ng  4 , Lisa Todd  5 , Wendyl J D'Souza  6
Affiliations
Free article

Quality of life and its association with comorbidities and adverse events from antiepileptic medications: Online survey of patients with epilepsy in Australia

Jeremy M Welton et al. Epilepsy Behav. 2020 Mar.
Free article

Abstract

Objective: This study aimed to explore the quality of life (QoL) of adult patients with epilepsy (PwE) in Australia and its relationship with comorbidities and adverse events (AEs) from antiepileptic drugs (AEDs).

Methods: Cross-sectional surveys were completed by PwE, or carer proxies, recruited via the online pharmacy application MedAdvisor and Australian PwE Facebook groups from May to August 2018. Data were collected on demographics, epilepsy severity and management, AEs, comorbidities, and QoL (using the Patient-Weighted Quality of Life in Epilepsy Inventory [QOLIE-10-P] total score). Two linear regression models were constructed to explore associations between AEs or comorbidities and QOLIE-10-P score, with possible confounders determined using stepwise selection.

Results: Nine hundred and seventy-eight of 1267 responses were eligible (mean age of respondents: 44.5 years, 64% female, 52% employed). Recent AED use was reported by 97%; 47% were on AED monotherapy, 35% had ≤2 lifetime AEDs, and 55% were seizure-free for >1 year. After stepwise selection, control variables included in both models were time since diagnosis, employment status, seizure frequency, number of currently prescribed AEDs, and number of general practitioner (GP) visits per year. In the model for comorbidities, "psychiatric disorders" was associated with the largest QOLIE-10-P score decrease (-23.14, p < 0.001). In the model for AEs, which additionally controlled for depression and anxiety disorder, self-reported "memory problems" was associated with the largest decrease in QOLIE-10-P score (-14.27, p < 0.001).

Conclusions: In this survey of Australian PwE, many of whom had relatively well-controlled epilepsy, psychiatric and self-reported memory problems were common and associated with the greatest detrimental impact on QoL. Further research is needed to better understand the underlying causes of impaired QoL and thereby improve its management.

Keywords: Adverse events; Antiepileptic drugs; Australia; Comorbidities; Cross-sectional; Quality of life.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest JW is an employee of UCB Pharma. CW is CEO of Chronic Illness Alliance Inc. Australia and Board member of Epilepsy Foundation Australia. CW has received funding from UCB Pharma to contribute to this research. KR has received speaker honoraria, travel support, advisory board honoraria, and/or research funding from: UCB Pharma, Eisai Australia, Novartis Pharmaceuticals, Zogenix International Inc., AFT Pharmaceuticals Ltd., LivaNova Australia Pty Ltd., and Janssen-Cilag Pty Ltd. AN is an employee of Costello Medical Singapore Pte Ltd., which provided data analysis and editorial services for the study. LT is an employee of Epilepsy Action Australia and has no disclosures to declare. WD's salary is part-funded by The University of Melbourne. He has received travel, investigator-initiated, and speaker honoraria from UCB Pharma; investigator and speaker honoraria from Eisai Australia; educational grants from Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and Sanofi-Synthélabo; educational, travel, and fellowship grants from GSK Neurology Australia; advisory board honoraria from LivaNova PLC and Tilray Inc.; and honoraria from ScieGen Pharmaceuticals.

Publication types

Substances